A Phase 2/3, Multicenter, Double-Blind, Randomized Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) vs Idursulfase in Pediatric and Young Adult Participants With Neuronopathic or Non-Neuronopathic Mucopolysaccharidosis Type II

This is a Phase 2/3, multiregional, two-arm, double-blind, randomized, active (standard-of-care)-controlled study of the efficacy and safety of tividenofusp alfa (DNL310), an investigational central nervous system (CNS)-penetrant enzyme-replacement therapy (ERT) for mucopolysaccharidosis type II (MPS II).
Participants may also qualify to enter an open-label treatment phase with DNL310 or idursulfase based on pre-specified criteria.

开始日期2022-07-21

申办/合作机构

Denali Therapeutics, Inc.

NCT04251026

/ Active, not recruiting临床1/2期

A Phase 1/2, Multicenter, Open-Label Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of DNL310 in Pediatric Participants With Hunter Syndrome

This is a multicenter, multiregional, open-label study to assess the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of tividenofusp alfa (DNL310), an investigational central nervous system (CNS)-penetrant enzyme replacement therapy (ERT), designed to treat both the peripheral and CNS manifestations of Mucopolysaccharidosis type II (MPS II; Hunter syndrome).
Participants, whose physicians feel they are deriving benefit, will have the opportunity to be reconsented into a safety extension and then an open-label extension for continued evaluation.

开始日期2020-07-16

申办/合作机构

Denali Therapeutics, Inc.

100 项与 Tividenofusp alfa 相关的临床结果

登录后查看更多信息

100 项与 Tividenofusp alfa 相关的转化医学

登录后查看更多信息

100 项与 Tividenofusp alfa 相关的专利（医药）

登录后查看更多信息

项与 Tividenofusp alfa 相关的文献（医药）

2026-01-01·NEW ENGLAND JOURNAL OF MEDICINE

An Intravenous Brain-Penetrant Enzyme Therapy for Mucopolysaccharidosis II

Article

作者: Zubizarreta, Imanol ; Engmann, Natalie J. ; Chin, Peter S. ; Muenzer, Joseph ; Bhalla, Akhil ; Burton, Barbara K. ; Harmatz, Paul ; Model, Fabian ; Troyer, Matthew D. ; Rajan, Deepa S. ; Watts, Ryan J. ; Ho, Carole ; Jones, Simon A. ; Mitchell, John J. ; Dong, Wei ; van den Hout, Johanna M.P.

BACKGROUND:

Tividenofusp alfa, comprising iduronate-2-sulfatase fused to an engineered transferrin receptor-binding Fc domain, has been developed to treat neurologic and peripheral manifestations of mucopolysaccharidosis type II (MPS II), a rare lysosomal disorder causing progressive multisystem and neurologic decline.

METHODS:

We conducted a phase 1-2, open-label study in which male participants up to 18 years of age with MPS II received weekly intravenous tividenofusp alfa for 24 weeks, followed by an 80-week safety extension and a 157-week open-label extension. The primary objective was to evaluate the safety of tividenofusp alfa. Secondary objectives were to evaluate central nervous system and peripheral effects as assessed by cerebrospinal fluid (CSF) and urinary heparan sulfate levels, adaptive behavior (as assessed with the Vineland Adaptive Behavior Scales), and liver volume.

RESULTS:

A total of 47 male participants were enrolled. At the 24-week primary analysis, all 47 participants reported at least one adverse event that emerged during the treatment period, most commonly infusion-related reactions. Pyrexia, urticaria, and vomiting were the most frequently reported symptoms of infusion-related reactions, occurring in more than 40% of the participants, despite routine premedication. Three participants had serious treatment-related adverse events; all continued to receive treatment. CSF and urinary heparan sulfate levels appeared to be reduced from baseline by 91% and 88%, respectively. Across all study periods, adverse events remained common. Reductions in heparan sulfate levels appeared to be maintained through week 153, adaptive behavior stabilized or improved, and liver volumes normalized or remained normal.

CONCLUSIONS:

In participants with MPS II, tividenofusp alfa treatment was commonly associated with adverse events. Heparan sulfate, the primary substrate that accumulates in the CSF and urine in persons with MPS II, appeared to decrease to levels within the range of unaffected children. A randomized trial is ongoing to further evaluate these effects. (Funded by Denali Therapeutics; ClinicalTrials.gov number, NCT04251026; EudraCT number, 2019-004909-27.).

2021-10-08·JCI insight1区 · 医学

Iduronate-2-sulfatase transport vehicle rescues behavioral and skeletal phenotypes in a mouse model of Hunter syndrome

1区 · 医学

ArticleOA

作者: Zhu, Yuda ; Chiu, Chi-Lu ; Tsogtbaatar, Buyankhishig ; Simms, Jeffrey ; Gill, Thomas M ; Speckart, Jessica ; Harris, Jeffrey M ; Costanzo, Simona ; Lopez, Isabel A ; Nguyen, Hoang N ; Thomsen, Elliot R ; Henry, Anastasia G ; Chan, Darren ; Holtzman, Julia ; Meisner, René ; Solanoy, Hilda ; Dugas, Jason C ; Henne, Kirk R ; Fang, Meng ; Delucchi, Anthony ; Arguello, Annie ; Sanchez, Pascal E ; Bhalla, Akhil ; Lo, Iris ; Diaz, Dolores ; Ravi, Ritesh ; Scearce-Levie, Kimberly ; Cheng, Yuhsiang

Mucopolysaccharidosis type II (MPS II) is a lysosomal storage disorder caused by deficiency of the iduronate-2-sulfatase (IDS) enzyme, resulting in cellular accumulation of glycosaminoglycans (GAGs) throughout the body. Treatment of MPS II remains a considerable challenge as current enzyme replacement therapies do not adequately control many aspects of the disease, including skeletal and neurological manifestations. We developed an IDS transport vehicle (ETV:IDS) that is engineered to bind to the transferrin receptor; this design facilitates receptor-mediated transcytosis of IDS across the blood-brain barrier and improves its distribution into the brain while maintaining distribution to peripheral tissues. Here we show that chronic systemic administration of ETV:IDS in a mouse model of MPS II reduced levels of peripheral and central nervous system GAGs, microgliosis, and neurofilament light chain, a biomarker of neuronal injury. Additionally, ETV:IDS rescued auricular and skeletal abnormalities when introduced in adult MPS II mice. These effects were accompanied by improvements in several neurobehavioral domains, including motor skills, sensorimotor gating, and learning and memory. Together, these results highlight the therapeutic potential of ETV:IDS for treating peripheral and central abnormalities in MPS II. DNL310, an investigational ETV:IDS molecule, is currently in clinical trials as a potential treatment for patients with MPS II.

114

项与 Tividenofusp alfa 相关的新闻（医药）

2026-02-25

·BioSpace

Cashing In on ‘Creative Fundamentals’ To Fund Rare Disease R&D

iStock, phive2015 Rare disease drug developers struggle to survive in a biopharma investment market that prioritizes large patient populations. Initiatives like the Orphan Therapeutics Accelerator are attempting to solve what CEO Craig Martin says is not a science problem, but a math problem. The rare disease space got a huge boost last month when the FDA’s rare pediatric disease priority review voucher program was reauthorized after more than a year in limbo. While a step in the right direction, rare and orphan drug leaders say more needs to be done to attract investment for these often-niche programs. “That was, I think, a great legislative victory,” MediciNova Chief Business Officer David Crean said of rare pediatric disease priority review vouchers (PRVs). Craig Martin, founder and CEO of the Orphan Therapeutics Accelerator (OTXL), agreed. “There’s some progress at least,” he told BioSpace at Phacilitate’s Advanced Therapies Week earlier this month, referring to PRVs and recent updates to the U.S. newborn screening program . The rare disease space has also seen a number of regulatory wins recently. This week, the FDA provided highly anticipated guidance for its plausible mechanism pathway for personalized therapies, first announced in November 2025. Two months before that, the agency unveiled its new Rare Disease Evidence Principles framework, intended to streamline the approval of therapies for ultra-rare diseases. But while the regulatory piece is rapidly evolving, the very nature of rare—and particularly ultrarare—diseases, poses a significant investment quagmire for the traditional biotech model, which assumes access to deep public equity markets, Crean said. This is largely due to the small—and sometimes minuscule—number of people affected with these diseases. There are more than 10,000 rare diseases, defined as those affecting fewer than 200,000 people, according to the Rare Disease Company Coalition. Ultrarare conditions , afflicting less than 1,000, offer an even smaller market opportunity. OTXL estimates more than 9,000 indications fit this definition. “Small patient populations mean lower peak revenue potential per indication and that changes the whole risk-return calculus for traditional VCs,” Crean said. Kristen Hege, former SVP of Early Clinical Development, Hematology/Oncology & Cell Therapy at Bristol Myers Squibb, agreed, saying, “Right now, as a rule of thumb, if your product isn’t going to bring in a billion dollars a year, it’s not going to be developed.” Alternative Models This dilemma was the impetus behind OTXL. Prior to 2022, the rare disease drug development space had already begun to stall from both a market and a policy perspective, Martin said. Provisions from the Inflation Reduction Act, signed into law in August 2022, further eroded confidence and commercial viability of these treatments. “A number of these programs were ones that had advanced into trials, were helping children in particular, and yet weren’t moving forward,” he said. “I was haunted by the fact that there were so many of these treatments that could be helping patients, and it wasn’t a science problem; it was a math problem.” OTXL obtains , funds and completes development of these shelved assets, leveraging a network of partners and its tax-exempt status as a nonprofit to lower costs. This tax exemption “incentivize[s] companies that were maybe sitting on an asset to liberate it and allow us to move it forward and to reduce or eliminate upfront costs for licensing or obtaining that asset,” he explained. The company has built relationships with a network of CROs and CDMOs, with whom it works on a deferred or reduced cost basis to further decrease the funding required for late-stage drug development in particular, Martin said. Since its launch in 2024, OTXL has considered more than 60 programs focused on ultrarare diseases, according to Martin, many of which are cell and gene therapies for pediatric conditions. OTXL can’t adopt them all, of course, so the organization is working on an AI-based platform that would allow it to ingest data rooms, vet investigational therapies, perform predictive modeling and conduct development planning, all intended to attractively package the assets for companies or investors to take on. Once a therapy wins regulatory approval, OTXL works with partners and employs alternative approaches—including its tax-exempt subsidiary Orphan Therapies —to ensure access. Recently, OTXL partnered with Italy-based Fondazione Telethon, which in December 2025 won FDA approval for Waskyra, a gene therapy for Wiskott-Aldrich syndrome. Fondazione Telethon, the first non-profit sponsor to secure FDA approval for a gene therapy, was looking for a U.S.-based commercial partner to support Waskyra’s launch this year when OTXL stepped up. With Waskyra,“We kind of got to commercial stage a little faster than we thought we would,” Martin said. Next up, the nonprofit is finalizing terms of an agreement for its first clinical-stage asset, an AAV gene therapy. While Martin declined to reveal the exact program or disease area, he said that compared to Waskyra—which might have a market reach of five to seven patients per year—the condition “is a little bit closer to the cusp of what a biotech might be willing to take on once we further de-risk it.” Rare diseases FDA Greenlights First Gene Therapy for Rare Pediatric Disease Backed by Italy-based Fondazione Telethon ETS, Waskyra, for Wiskott-Aldrich syndrome, is the first gene therapy from a non-profit sponsor to win FDA approval. December 10, 2025 · 1 min read · Tristan Manalac The challenges faced by rare disease drug developers sometimes mean a company is forced to sell off multiple assets or fold entirely. Hege sat on the board of Adaptimmune until the biotech sold its cell therapy portfolio, including synovial sarcoma cell therapy Tecelra, to US WorldMeds in July 2025. Approved by the FDA in August 2024, Tecelra was the first engineered T cell therapy approved for solid tumor cancers in the U.S. “That was a major accomplishment for the field of cell therapy,” Hege said. “Unfortunately, Adaptimmune wasn’t really able to make it commercially viable enough to continue as a standalone company. “Synovial sarcoma is a pretty rare indication, so you couldn’t get a lot of Big Pharma or venture investor interest in that small market opportunity,” Hege continued, calling this a “fundamental problem with our drug development system.” Hege is working with the nonprofit Friends of Cancer Research, which aims to drive collaboration among industry, scientists and policy makers, to devise a strategy to advance breakthrough therapies for “uncommon” cancer indications, including sarcoma, small cell lung cancer, pancreatic cancer and “pretty much every” pediatric cancer. These indications “are still not commercially attractive to drive investment in our current paradigm of cancer R&D,” Hege said. For companies intrepid enough to attempt to traverse the complex rare disease market, the experts who spoke to BioSpace offered advice. “Capital efficiency is super critical here,” said Crean, whose company, MediciNova, faces the additional hurdle of developing treatments in the notoriously challenging neurodegenerative disease space. “It almost becomes a part of the strategic imperative.” Crean recommended employing shared infrastructure across rare disease assets and staged development strategies aimed at reaching meaningful clinical milestones with less capital deployed per stage. In terms of fundraising options for rare disease-focused companies, Crean noted the “creative fundamentals,” including royalty financing, which he is becoming more prevalent. Deals Royalty Financing Serves as Lifeline for Some Biopharma Companies in Uncertain Market As traditional fundraising methods falter for smaller firms, the rise of royalty deals is reshaping how companies access capital, offering an alternative that bypasses equity dilution and debt. October 2, 2024 · 5 min read · Ben Hargreaves Read more Revolution Medicines last month signed a $2 billion deal with Royalty Pharma to support its portfolio of treatments for RAS-addicted malignancies, including pancreatic cancer. Royalty, which buys royalties on future sales in exchange for non-dilutive capital, counts Roche’s Evrysdi for spinal muscular atrophy and Denali’s tividenofusp alfa for Hunter syndrome—which has an FDA action date in April—among its portfolio. Regulatory incentives, such as FDA orphan drug and breakthrough therapy designations, along with PRVs, also need to be incorporated into the strategic and capital financing strategy, Crean said. Part of the solution could actually be on the regulatory side, Hege said. “What does it take in these uncommon cancers to get a product approved? Because in our country, until a product is approved, payers don’t pay for the product, so the cost of development is all borne by the sponsor.” These costs include product manufacturing and clinical trials. Hege suggested a model of shared risk between sponsor and payer, where the payer covers the cost for a product in development, or a regulatory process where the asset is granted accelerated approval earlier in its development course, “at which point it is an FDA-approved product, and the payers have to pay.” This would be followed by a post-marketing agreement to run larger, more expensive trials. “I think when the unmet need is high enough,” Hege said, “we just have to become more risk tolerant.”

孤儿药上市批准优先审批突破性疗法细胞疗法

2026-02-23

·罕见病

7年独占期+基因编辑突破：2026年罕见病患者等来春天

2026年1月，一种曾让患儿“活不过3岁”的Menkes病终于迎来首个获批疗法。当7年市场独占期政策落地，罕见病药物研发从“赔本买卖”变成了“黄金赛道”，无数患者和家庭迎来了真正的希望。政策红包：7年独占期让药企抢着做罕见病药 2026年1月，国务院总理签署国务院令公布新修订的《中华人民共和国药品管理法实施条例》，自2026年5月15日起施行。其中，对符合条件的罕见病药品给予不超过7年的市场独占期，为药企投入罕见病药物研发提供了强大动力，标志着中国罕见病领域从“快速通道”迈向“高收益保护”的黄金时代。为保障这7年市场保护落地，CDE构建了“1+n”指导原则体系。《模型引导的罕见疾病药物研发技术指导原则(2025版)》鼓励通过MIDD（用数学模型代替真人试药）进行人群外推，解决儿童罕见病受试者招募难题。截至2026年初，CDE公示多款入选“关爱计划”的试点产品，辉瑞的马塔西单抗（Marstacimab）成为行业首个试点产品，用于治疗12岁及以上不伴抑制物的A型或B型血友病。技术破局：RNAi和基因编辑正在改写死亡倒计时 2026年，多款罕见病创新药物将获批上市，为患者带来了新的治疗希望。渐冻症：RNAi疗法实现颠覆性突破蔡磊团队研发的RAG-17、RAG-21等核心药物，采用RNA干扰技术（RNAi，一种能精准“沉默”致病基因的技术），能精准“沉默”SOD1、FUS等致病基因，从根源减少毒性蛋白生成，真正实现对因治疗。其中RAG-17成为全球首个在中美同步获批临床试验的渐冻症疗法，RAG-21也获得美国FDA孤儿药资格。2026年年初刚刚启动二期临床。Menkes病：FDA批准首个疗法打破“活不过3岁”魔咒 2026年1月11日，美国食品药品监督管理局（FDA）正式批准了Sentynl Therapeutics公司开发的Zycubo（组氨酸铜）注射液，这是FDA批准的首个针对Menkes病儿科患者的疗法。这种突破性疗法绕过了患儿肠道吸收铜的遗传缺陷，通过皮下注射直接将铜输送到体内。简单说，以前这些孩子像漏水的桶，补多少铜都存不住；现在直接绕过漏洞往身体里输铜，死亡率直降78%。研究结果显示，出生后4周内开始治疗的儿童，与未治疗组相比死亡风险降低了78%。近一半早期接受治疗的患者存活超过6年，部分患者甚至活过12年；而未治疗对照组中，没有患者存活超过6年。亨特综合征：突破血脑屏障的酶替代疗法 2026年1月1日，《新英格兰医学杂志》发表了Denali Therapeutics公司开发的Tividenofuspalfa用于治疗亨特综合征的开放标签1/2期临床试验结果。该研究表明，这款基于其专有TransportVehicle™技术平台开发的DNL310不仅成功跨越了血脑屏障（BBB，大脑的天然“防盗门”，90%的药物都进不去），更是在降低中枢神经系统（CNS，大脑和脊髓的总称）损伤标志物方面表现出卓越疗效。在为期24周的主要分析中，关键次要结果显示，脑脊液和尿液中的硫酸乙酰肝素水平在第24周时分别较起始降低了91%和88%。基因编辑：从“实验室”到“临床应用” 2026年，基因编辑技术不再是实验室里的遥远概念，而是成为拯救罕见病患者的“定制化武器”。据报道，美国费城儿童医院的临床试验震惊医学界：一名患有罕见尿素循环障碍的婴儿，通过个性化碱基编辑疗法重获新生。与传统基因编辑不同，这种“分子铅笔”技术无需切断DNA双链，仅针对患者特有的CPS1基因突变精准修正，治疗后婴儿氨水平显著降低，已能正常摄入蛋白质。中国在该领域同样实现“弯道超车”。国产眼科基因编辑疗法GEB-101获FDA批准临床试验，成为全球首个针对遗传性致盲眼病的体内编辑疗法。其核心突破在于采用RNP递送系统，编辑完成后快速降解，将脱靶风险降至极低，为全球数千万角膜营养不良患者带来根治希望。而华中科技大学发现的AcrIIA5蛋白，更让精准编辑效率提升8.2倍，彻底解决了此前技术效率不足的瓶颈。这一突破如果得到进一步验证，将标志着中国在基因编辑领域的重大进展。医保落地：从“天价药”到“用得起” 2026年，医保政策将继续向罕见病患者倾斜。除了全国统一执行的罕见病医保倾斜政策外，部分地区在国家政策基础上进一步提高了报销比例。德阳市、成都市、泸州市、遂宁市、石棉县等多地已同步实施，将保障病种扩展至与全省统一的62个大类（细分亚类85种），涵盖慢性病33类、特殊病29类。为方便患者，部分省份明确支持对病情稳定的患者开具最长12周（约3个月）的长期处方。此外，多地优化了线上认定和省内异地就医结算流程，提升了服务便捷性。 2025年版国家医保目录于2026年1月1日起全面落地执行，新增10种罕见病特效药，覆盖脊髓性肌萎缩症、戈谢病、血友病等以往用药贵、用药难的病种。经医保谈判后平均降价超70%，部分天价药降幅更是高达95%。一种曾经年花费百万的罕见病特效药，现在医保报销后患者自付不到5万。还实现零自付、单列支付，搭配3分钟线上备案、双通道直接结算，不用先垫付再跑腿，给无数罕见病家庭卸下了沉重负担。携手同行，共筑希望尽管罕见病诊疗领域取得了诸多突破，但仍面临着许多挑战。例如，罕见病的诊断仍然困难，很多患者需要经历漫长的诊断过程；部分罕见病药物价格昂贵，即使纳入医保，患者的经济负担仍然较重；还有许多罕见病仍然没有有效的治疗方法。不过，随着政策的支持、技术的进步和社会关注度的提高，罕见病诊疗领域的未来充满希望。2026年，让我们携手同行，共筑希望。让我们相信，在不久的将来，更多的罕见病将得到有效的诊断和治疗，更多的罕见病患者将重获健康和希望。你身边有罕见病患者吗？2026年的这些突破，哪一个让你最感动？评论区聊聊。转发这篇文章，让更多人看到罕见病群体的希望。

2026-02-19

·GlobeNewswire-Health Care

Drug-Delivery Breakthroughs, Cross-Indication Research Accelerate New Momentum in CNS and Oncology Development

AUSTIN, Texas, Feb. 19, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Biotechnology mergers and acquisitions (M&As) are increasingly shaped by a clear strategic evolution. Pharmaceutical companies are prioritizing clinical-stage and late-stage programs supported by human data rather than early discovery platforms with uncertain timelines. Following a period where capital heavily favored preclinical innovation, investors and acquirers are now focusing on assets that demonstrate safety signals, efficacy data and clearer pathways toward commercialization. Within this shifting landscape, companies holding diversified clinical-stage portfolios across oncology and central nervous system (CNS) indications are drawing renewed attention. One such example is Oncotelic Therapeutics Inc. (OTCQB: OTLC) (profile), which recently announced expanded international intellectual property coverage for OT-101, its proprietary TGF-β antisense therapeutic platform. The development strengthens protection across neurology, oncology and CNS drug-delivery technologies aimed at crossing the blood–brain barrier. This evolving M&A environment highlights Oncotelic’s positioning within oncology and CNS innovation alongside industry leaders such as Denali Therapeutics Inc. (NASDAQ: DNLI), Roche Holdings AG (OTCMKTS: RHHBY), Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY) and Wave Life Sciences Ltd. (NASDAQ: WVE). Central nervous system disorders represent one of the largest and most complex therapeutic areas globally. The convergence of CNS and oncology research amplifies the significance of Oncotelic’s recent intellectual property updates for OT-101. Oncotelic’s emphasis on delivery technologies relevant to CNS and oncology supports this evolving industry direction. Oncotelic Therapeutics’ work with OT-101 reflects a repositioning strategy that seeks to broaden clinical utility by applying an established mechanism across multiple oncology indications. Oncotelic Therapeutics has structured its portfolio to span oncology-focused therapies, central nervous system indications and advanced delivery technologies. Click here to view the custom infographic of the Oncotelic Therapeutics editorial. Pharma Prioritizes Clinically Validated Programs Biopharmaceutical deal activity increasingly reflects a preference for external innovation through licensing arrangements, partnerships and targeted acquisitions of programs that have already achieved clinical validation. Assessments from McKinsey & Company describe the growing reliance on external pipeline sourcing as companies face challenges in internal research productivity. Similarly, Deloitte’s life sciences M&A overview highlights careful selectivity among buyers, emphasizing disciplined capital deployment toward assets demonstrating measurable development progress. This strategic realignment reflects the economic facts of drug development. Long timelines and rising costs have pushed investors and pharmaceutical companies toward programs with established human safety and efficacy data. Late-stage candidates reduce scientific uncertainty by providing clearer insights into dosing, safety profiles and regulatory prospects. Consequently, assets approaching pivotal trials or advanced clinical phases are attracting greater interest from companies seeking accelerated routes to commercialization. Within this framework, oncology and CNS programs have emerged as particularly attractive targets. Oncology remains a dominant area of investment due to large commercial markets and continuous innovation, while CNS disorders represent a major unmet medical need globally. Programs that bridge these fields offer differentiated positioning, particularly when they address complex signaling pathways or drug delivery challenges that historically limited treatment success. Platforms that provide human clinical data also offer valuation benefits. Demonstrated clinical activity provides tangible milestones for investors to assess, reducing risk compared with early discovery platforms. This trend is driving attention toward companies with diversified clinical-stage portfolios rather than single preclinical assets. Oncotelic Therapeutics reflects this strategic profile through its clinical-stage pipeline targeting oncology and CNS-related mechanisms. The company is advancing therapies focused on cancer and serious neurological conditions, including approaches targeting TGF-β signaling and innovative delivery methods designed to improve therapeutic outcomes. CNS, Oncology Research Paths Converge Central nervous system disorders represent one of the largest and most complex therapeutic areas globally. The World Health Organization reports neurological conditions among the leading causes of disability worldwide, affecting more than one-third of the global population. The growing burden of neurodegenerative diseases has intensified demand for innovative therapeutic approaches capable of addressing complex biological pathways. Alzheimer’s disease highlights the scale of unmet need, with millions of individuals affected and significant economic implications for healthcare systems. Parkinson’s disease prevalence is also expected to increase as populations age, further reinforcing the importance of innovation within CNS research. The juncture between oncology and neurological research continues to expand as scientists recognize overlapping biological mechanisms. Immune regulation, inflammation and cellular signaling pathways involved in tumor biology also influence neurological disease processes. These overlaps produce chances for therapeutic platforms that can address multiple indications, expanding commercial potential while leveraging shared scientific understandings. From an investment outlook, cross-indication platforms could provide tactical advantages by enabling companies to focus on diverse therapeutic markets concurrently. Pharmaceutical acquirers often favor mechanisms with applicability beyond a single disease area, as this can support broader lifecycle management and enhance return potential. Oncotelic’s strategy reflects this convergence through its work on TGF-β modulation, a pathway extensively studied in oncology and immune regulation. Research highlights TGF-β signaling as a critical component of tumor microenvironment biology, reinforcing the potential relevance of targeting this mechanism across multiple disease categories. New IP Milestones Strengthen Platform The convergence of CNS and oncology research amplifies the significance of Oncotelic’s recent intellectual property updates for OT-101. Developed in collaboration with Sapu Bioscience, the expanded patent coverage strengthens protection across neurology, oncology and CNS drug delivery applications. OT-101 has undergone prior clinical trials across multiple oncology indications, including glioblastoma and pancreatic cancer. The compound has also been evaluated for additional indications such as acute respiratory distress syndrome and COVID-19-related inflammatory conditions. Building on this clinical foundation, the company is advancing OT-101 as a broader CNS-capable platform supported by delivery technologies and expanded IP protection. Recent patent developments include allowed claims in Australia covering Parkinson’s disease treatment applications and utility model patents in China and Germany protecting device-level intracranial infusion technologies. According to company statements, these developments establish an integrated commercialization platform combining therapeutic use claims with delivery-device protection, strengthening OT-101’s long-term strategic value. “OT-101 has a well-established clinical foundation, including prior clinical trials in multiple oncology indications, including glioblastoma, and these new IP milestones significantly expand its long-term potential,” said Oncotelic CEO Dr. Vuong Trieu. “By securing Parkinson's disease claims in Australia and strengthening CNS delivery protection in China and Germany, we are building a globally defensible platform that supports both therapeutic use and delivery, while positioning the company for strategic partnerships and long-term shareholder value creation.” Drug-Delivery Innovation Gains Strategic Importance Drug-delivery technology has become an increasingly important differentiator in biotechnology innovation, particularly within CNS therapeutics. The blood–brain barrier represents a significant obstacle, preventing many therapeutic compounds from reaching effective concentrations within brain tissue. Scientific research continues to emphasize how this biological barrier limits treatment victory even when compounds demonstrate strong activity in early testing As a result, delivery systems capable of improving targeting and bioavailability are increasingly important. Researchers are becoming more likely to view delivery platforms as enabling technologies capable of unlocking therapeutic pathways that were previously considered inaccessible. Rather than treating delivery as secondary to molecular innovation, developers and investors are recognizing it as a critical component of therapeutic success. Regulatory agencies have also acknowledged the growing importance of delivery innovation. The U.S. Food and Drug Administration provides frameworks for evaluating combination products that integrate drug and device components, reflecting the role administration methods play in clinical outcomes. Oncotelic’s emphasis on delivery technologies relevant to CNS and oncology supports this evolving industry direction. By focusing on approaches designed to enhance targeting and overcome biological barriers, the company is working within an area increasingly viewed as a strategic value driver in modern drug development. Repositioning Strategies Improve Capital Efficiency Biotechnology companies are placing growing importance on capital efficiency, leading to increased adoption of strategies that extend clinically supported mechanisms into new therapeutic areas. Instead of initiating entirely new discovery pipelines from scratch, developers are leveraging established platforms and applying them to related disease indications where underlying biology and prior research provide a strong scientific foundation. Biotechnology development models are increasingly shaped by a focus on maximizing efficiency and extending the value of existing research. One approach gaining traction involves advancing clinically supported mechanisms into new therapeutic areas, allowing companies to build upon established scientific foundations rather than launching entirely new discovery programs. By applying validated platforms to adjacent disease categories where biological relevance already exists, developers can broaden potential applications while leveraging prior knowledge. This strategy can help reduce development risk because earlier clinical experience provides insights into safety profiles, dosing considerations and underlying mechanisms of action. Expanding a platform across multiple indications also enables companies to extract greater value from prior investments, creating additional clinical opportunities from a single technology or biological target while potentially accelerating timelines compared with starting from first principles. The TGF-β pathway illustrates this strategy effectively. Scientific text describes its involvement in tumor progression, immune regulation and inflammation, creating opportunities for therapies targeting this pathway across diverse disease areas. Advances in understanding tumor microenvironment biology have renewed interest in therapies that modulate TGF-β signaling. Oncotelic Therapeutics’ work with OT-101, a therapeutic designed to target TGF-β2 mRNA, reflects a repositioning strategy that seeks to broaden clinical utility by applying an established mechanism across multiple CNS indications. Supported by prior clinical data and biological rationale, ongoing studies evaluating OT-101 alongside standard-of-care treatments demonstrate continued efforts to expand its therapeutic scope and explore new potential applications. Adopting a platform-based repositioning strategy can also provide greater strategic flexibility for future collaborations or acquisitions. Companies able to apply a single mechanism across diverse disease settings may be better positioned to adapt to changing market dynamics, scientific developments or regulatory environments, ultimately enhancing long-term development pathways and partnership opportunities. Multiple Programs Help Mitigate Clinical Risk Biotech investment has traditionally gravitated toward single-asset companies, where valuation and investor sentiment were often tied closely to the success or failure of one clinical program. Increasingly, however, diversified pipelines are being recognized as a more balanced model because they spread development risk across multiple candidates and timelines rather than concentrating exposure in a single outcome. Maintaining several active programs can provide greater stability throughout the clinical process, since delays or challenges affecting one asset may be offset by forward progress in others. This broader development strategy can also introduce multiple potential catalysts, creating additional opportunities for value creation and appealing to investors who seek exposure to innovation while minimizing reliance on binary events. From a strategic transaction perspective, companies with diversified portfolios may offer enhanced appeal to potential acquirers. Access to multiple therapeutic assets within a single acquisition provides flexibility, allowing larger pharmaceutical organizations to prioritize programs based on evolving scientific insights, regulatory developments or shifting market dynamics. As industry priorities increasingly emphasize clinical validation, adaptable platforms and efficient capital deployment, organizations combining diversified pipelines with differentiated scientific approaches may attract heightened interest from partners and buyers looking to balance innovation potential with reduced development risk. Within this framework, Oncotelic Therapeutics has structured its portfolio to span oncology-focused therapies, central nervous system indications and advanced delivery technologies. By advancing multiple programs at different stages of development, the company seeks to reduce dependence on any single clinical outcome while supporting a broader strategic pathway for growth and collaboration. Breaking Through the Brain’s Treatment BarriersAdvances in drug delivery are rapidly reshaping the therapeutic landscape, particularly as innovators push beyond traditional barriers that have historically limited treatment of CNS and neurological disorders. Recent developments across the sector highlight growing momentum in technologies designed to transport therapies into the brain, refine precision targeting at the molecular level and expand treatment possibilities for complex neurodegenerative and rare genetic diseases. Denali Therapeutics Inc. (NASDAQ: DNLI) is reporting data that highlights the potential of its Enzyme TransportVehicle(TM) (ETV) to enable the delivery of enzyme replacement therapies (ERT) to the whole body, including the brain. The data is from programs in Hunter syndrome (mucopolysaccharidosis type II, MPS II), Sanfilippo syndrome type A (MPS IIIA) and Pompe disease. The data was presented at the 22nd annual WORLDSymposium(TM). The company noted that the presented data reflects “the strong momentum of our Enzyme TransportVehicle franchise as we continue to prepare for the potential commercial launch of tividenofusp alfa for Hunter syndrome and make meaningful progress across lysosomal storage disorders.” Roche Holdings AG (OTCMKTS: RHHBY) proprietary Brainshuttle(TM) technology opens up new options for delivering medicine to the brain. Scientists at Roche have been working on building a platform that could help transport medicines safely across the blood-brain barrier since 2008, and the company ultimately delivered a way for medicines to cross the blood-brain barrier that is in clinical trials: the Brainshuttle technology. “The Brainshuttle technology has created enormous momentum in the industry,” said Niels Janssen, senior principal scientist in pharmacokinetics and pharmacodynamics in Roche’s Pharma Research and Early Development. “We’ve flipped the conversation from if it works to how well it works.” Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY) is highlighting its ongoing advancement of the company’s RNA interference (RNAi) platform strategy, including conjugate-based approaches designed to expand delivery into new tissues such as the central nervous system. In its most recent corporate update, the company reported continued progress across its RNAi pipeline, including the initiation of phase 1 and phase 2 clinical trials of investigational RNAi therapeutics, and the planned expansion of its state-of-the-art manufacturing facility in Norton, Massachusetts, designed to develop the industry's first fully dedicated, proprietary siRNA enzymatic-ligation manufacturing facility. Wave Life Sciences Ltd. (NASDAQ: WVE) has reported on WVE-003, its first-in-class, allele-selective oligonucleotide for the treatment of Huntington’s disease (HD). The company noted that in the SELECT-HD clinical trial, data demonstrated the first-ever allele-selective reduction in CSF mHTT protein and preservation of healthy, wtHTT with multiple doses of WVE-003, as well as a statistically significant correlation between mHTT reduction and slowing of caudate atrophy. By reducing mHTT at the mRNA and protein level, WVE-003 addresses underlying drivers of neurodegeneration. In addition, by sparing wtHTT protein, which is critical to the health of the central nervous system, WVE-003 is uniquely positioned to address individuals living with HD who are presymptomatic as well as those who are symptomatic. These milestones reflect a broader shift toward platform-driven innovation that prioritizes targeted delivery, advanced biologics and next-generation modalities capable of addressing previously inaccessible disease pathways. For more information, visit Oncotelic Therapeutics profile. About BioMedWire BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.BMW is where breaking news, insightful content and actionable information converge.To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)For more information, please visit https://www.BioMedWire.comDISCLAIMER: BioMedWire (BMW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by BMW are solely those of BMW. Readers of this Article and content agree that they cannot and will not seek to hold liable BMW for any investment decisions by their readers or subscribers. BMW is a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.The Article and content related to the profiled company represent the personal and subjective views of the Author and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, BMW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.BMW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may,” “future,” “plan,” or “planned,” “will,” or “should,” “expected,” “anticipates,” “draft,” “eventually,” or “projected.” You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and BMW undertakes no obligation to update such statements.Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/DisclaimerBioMedWireAustin, Texaswww.BioMedWire.com512.354.7000 OfficeEditor@BioMedWire.comBioMedWire is powered by IBN

临床2期寡核苷酸

100 项与 Tividenofusp alfa 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
黏多醣贮积症II型	申请上市	美国	Denali Therapeutics, Inc.	2025-04-02

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04251026 (Pubmed \| N Engl J Med)	临床1/2期	黏多醣贮积症II型	47	Tividenofusp alfa	醖壓糧蓋壓壓衊積糧鬱(製鑰糧範餘獵廠淵積齋) = 艱糧願遞艱鹽鑰鏇積夢獵窪淵醖窪鹹積夢齋願 (獵簾積夢壓鹽淵獵糧製 ) 更多	积极	2026-01-01
NCT04251026 (DNLI-E-0002, PipelineReview) 人工标引	临床1/2期	黏多醣贮积症II型	47	tividenofusp alfa	鏇積願觸醖醖衊構醖窪(鹽艱獵淵餘製鏇齋網繭) = including infusion-related reactions (IRRs), anemia, vomiting, pyrexia, respiratory infections, and rash. 衊選觸襯艱齋築顧壓醖 (簾齋繭獵衊壓憲鬱選壓 )	积极	2025-02-06
SSIEM2022	临床1/2期	黏多醣贮积症II型	26	DNL310	遞遞範遞鏇遞範願選構(襯壓衊網餘鏇鹹衊鹹窪) = infusion-related reactions (IRRs) occurred in 20/26 (76.9%) participants during the 24-week study, and 2/14 (14%) participants during the first 6 months of the SE 遞積衊衊遞鬱醖蓋網製 (顧簾壓網構衊鏇鑰醖淵 ) 更多	-	2022-08-30
Phase 1/2 Study (SSIEM2022)	临床1/2期	黏多醣贮积症II型	21	DNL310	獵蓋壓製鹽鏇鑰遞膚網(獵鬱鹹夢艱鹹鹽積簾遞) = 鏇壓願簾夢壓繭鏇獵蓋餘觸觸鏇觸淵廠蓋廠醖 (醖築鹹窪選鏇廠夢願鏇 ) 更多	积极	2022-08-30